LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 17, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that five abstracts related to its anti-HMGB1 (High Mobility Group Box 1) program were presented at the European Molecular Biology Organization (EMBO) Workshop, “Innate Danger Signals and HMGB1,” that was held in Milan, Italy. The anti-HMGB1 program is a collaboration between Critical Therapeutics and MedImmune, Inc.
